Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Target LDL-C for SVO Stroke
NCT06649240Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Oct 2024
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ulinastatin and ezetimibe in Lacunar stroke (LS) (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Major adverse cardiovascular event at 4 years. Started Oct 2024; status: recruiting.
02
Drugs
ulinastatinezetimibe
03
Conditions
Lacunar stroke (LS)
Beyond the preview
Go deeper on NCT06649240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649240.